TherapeuticsMD, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M | $64.9M | $49.6M | $16.1M |
| Cost of Revenue | — | — | — | $1.4M | $1.4M | $16.0M | $6.3M | $2.7M |
| Gross Profit | — | — | $1.3M | $68.6M | $1.2M | $48.9M | $43.3M | $13.4M |
| Gross Margin | — | — | 100.0% | 98.0% | 45.5% | 75.4% | 87.2% | 83.0% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $7.1M | $10.4M | $19.8M | $27.3M |
| SG&A Expense | $6.9M | $4.7M | $8.9M | $56.7M | $80.7M | $193.0M | $174.1M | $116.0M |
| Operating Income | $-4.4M | $-6.1M | $-8.5M | $1.2M | $-79.6M | $-155.5M | $-151.2M | $-130.2M |
| Operating Margin | -145.3% | -347.1% | -654.6% | 1.7% | -3,092.8% | -239.8% | -304.6% | -808.8% |
| Interest Expense | $8.0K | $10.0K | $300.0K | $200.0K | $32.9M | $28.6M | $17.4M | $4.7M |
| Pretax Income | $-653.0K | $-2.3M | $-7.7M | $1.1M | $-79.3M | $-183.5M | $-176.1M | $-132.6M |
| Income Tax Expense | — | $-31.0K | $-43.0K | — | — | — | — | — |
| Net Income | $-569.0K | $-2.2M | $-10.3M | $112.0M | $-172.4M | $-183.5M | $-176.1M | $-132.6M |
| Net Margin | -18.8% | -123.9% | -789.4% | 160.1% | -6,700.9% | -282.9% | -354.8% | -823.7% |
| EPS (Basic) | $-0.05 | $-0.19 | $-0.99 | $12.41 | $-21.66 | $-0.67 | $-0.72 | $-0.59 |
| EPS (Diluted) | $-0.05 | $-0.19 | $-0.99 | $11.96 | $-21.66 | $-0.67 | $-0.72 | $-0.59 |
| Shares Outstanding (Basic) | 11.6M | 11.5M | 10.4M | 9.0M | 8.0M | 275.6M | 246.4M | 240.5M |
| Shares Outstanding (Diluted) | 11.6M | 11.5M | 10.4M | 9.4M | 8.0M | 275.6M | 246.4M | 240.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |